Commentary on "cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949".
Tannock
I F
IF
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. ian.tannock@uhn.on.ca
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000601:surgery*; D009362:Neoplasm Metastasis; D009392:Nephrectomy / Q000379:methods*; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins